Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr Saad on the Association Between IL-7 SNPs and Immune-Related AEs in RCC

August 8th 2024

Eddy Saad, MD, MSc, discusses the association between an IL-7 SNP and immune-related AEs in patients with RCC who received immune checkpoint inhibitors.

Dr Uzzo on a Biomarker Analysis of the IMmotion010 Trial in RCC

July 31st 2024

Robert Uzzo, MD, MBA, FACS, discusses a biomarker analysis of the IMmotion010 trial in patients with renal cell carcinoma.

Bevacizumab Biosimilar Receives Approval in the European Union

July 30th 2024

The European Medicines Agency has approved Avzivi, a biosimilar referencing bevacizumab.

Uzzo Elucidates the Potential Role of KIM-1 as a Biomarker in RCC

July 30th 2024

Robert Uzzo, MD, details data from the IMmotion010 study on KIM-1 and how the biomarker could be used as well as future directions for investigating it in RCC.

Dr Dizman on the Impact of CBM588 on the Gut Microbiome in ICI-Treated Patients With RCC

July 29th 2024

Nazli Dizman, MD, discusses the impact of CBM588 on gut microbiome composition in patients with renal cell carcinoma who received immune checkpoint inhibitors in the first line.

Dr Rini on the Background of a Biomarker Analysis of KEYNOTE-426 in RCC

July 23rd 2024

Brian I. Rini, MD, FASCO, discusses an analysis of clustering from the KEYNOTE-426 study in patients with advanced renal cell carcinoma.

KIM-1 Demonstrates Potential Utility as a Biomarker With Worse DFS Outcomes in KIM-1–High RCC

July 21st 2024

Brian Rini, MD, details recent data in renal cell carcinoma surrounding the utility of KIM-1 as a potential biomarker and next steps for KIM-1 research.

Dr Machaalani on Overcoming Acquired Resistance Through AXL and c-Met Inhibition in RCC

July 19th 2024

Marc Machaalani, MD, discusses how inhibition of AXL and c-Met may prevent acquired resistance to c-Met inhibitors in renal cell carcinoma.

Clear Cell Histology Associated With Increased Risk of irAEs in Metastatic RCC

July 18th 2024

Razane El Hajj Chehade, MD, discusses a retrospective study of risk factors for irAEs in patients with metastatic renal cell carcinoma.

Nivolumab/Tivozanib Fails to Improve PFS in Advanced RCC After Prior Immune Checkpoint Inhibition

July 18th 2024

The addition of nivolumab to tivozanib did not improve PFS in advanced metastatic renal cell carcinoma following prior immune checkpoint inhibition

Dr Hajj Chehade on Potential Risk Factors for irAE Development in mRCC

July 18th 2024

Razane El Hajj Chehade, MD, discusses the association between different histologic subtypes in renal cell carcinoma and the risk of developing immune-related adverse effects.

Dr Cigliola on the Background of the SURE-01 Study in MIBC

July 17th 2024

Antonio Cigliola, MD, discusses the phase 2 SURE-01 study of neoadjuvant sacituzumab govitecan in muscle-invasive bladder cancer.

Dr Rini on a Biomarker Analysis of KEYNOTE-426 Using Subtype Clustering RCC

July 17th 2024

Brian I. Rini, MD, FASCO discusses findings from an exploratory analysis of the phase 3 KEYNOTE-426 study.

NCCN Updates Kidney Cancer Clinical Practice Guidelines

July 17th 2024

The National Comprehensive Cancer Network has published their updated Clinical Practice Guidelines in Oncology for kidney cancer.

Cabozantinib Plus Nivolumab Shows Efficacy With/Without Ipilimumab Across Advanced GU Malignancies

July 15th 2024

The addition of ipilimumab to cabozantinib plus nivolumab was safe and showed notable efficacy in patients with rare genitourinary cancers.

Belzutifan Yields PFS Advantage in Pretreated Advanced ccRCC Across Subgroups

July 12th 2024

Belzutifan generated superior efficacy and safety outcomes vs everolimus across prespecified subgroups of patients with previously treated advanced ccRCC.

Abemaciclib Monotherapy Does Not Elicit Responses in Advanced Renal Cell Carcinoma

July 12th 2024

Treatment with single-agent abemaciclib (Verzenio) did not demonstrate clinically meaningful activity in heavily treated patients with metastatic clear cell renal cell carcinoma.

Fianlimab Plus Cemiplimab Yields Early Efficacy Signs in Pretreated Advanced ccRCC

July 12th 2024

Fianlimab plus cemiplimab produced durable responses in heavily pretreated advanced clear cell renal cell carcinoma.

Belzutifan Shows Manageable, Pooled Safety Profile in Advanced VHL-Associated RCC

July 12th 2024

Most patients included in the post-hoc pooled analysis who were treated with belzutifan experienced an all-cause adverse effect.

Dr Semaan on Liquid Biopsy Epigenomic Profiling for the Detection of Sarcomatoid RCC

July 12th 2024

Karl Semaan, MD, MSc, discusses the utility of liquid biopsy epigenomic profiling for the detection of sarcomatoid renal cell carcinoma.